WO2007128133A1 - marqueur enferme dans un poil destine a detecter la fuite d'une prothese - Google Patents

marqueur enferme dans un poil destine a detecter la fuite d'une prothese Download PDF

Info

Publication number
WO2007128133A1
WO2007128133A1 PCT/CA2007/000818 CA2007000818W WO2007128133A1 WO 2007128133 A1 WO2007128133 A1 WO 2007128133A1 CA 2007000818 W CA2007000818 W CA 2007000818W WO 2007128133 A1 WO2007128133 A1 WO 2007128133A1
Authority
WO
WIPO (PCT)
Prior art keywords
tracer
prosthesis
hair
ofloxacin
extract
Prior art date
Application number
PCT/CA2007/000818
Other languages
English (en)
Inventor
David James Haddon
Steven James Maltby
Michael Anthony Long
Original Assignee
David James Haddon
Steven James Maltby
Michael Anthony Long
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David James Haddon, Steven James Maltby, Michael Anthony Long filed Critical David James Haddon
Publication of WO2007128133A1 publication Critical patent/WO2007128133A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

Definitions

  • This invention relates to the field of prostheses and fillers for prostheses.
  • this invention relates to the compositions that are enveloped or contained within prostheses their uses and methods for detecting leakage of those compositions from the prostheses.
  • MRI nuclear magnetic resonance imaging
  • Mammography can cause leakage of a prosthesis. Frequent CT scans are discouraged in order to reduce exposure to radiation. The sensitivity of ultrasonography is low, having a range of 32% and 74% accuracy.
  • MRI evaluation is inhibited by poor accessibility to diagnostic equipment, in terms of both financial restrictions and regional availability of necessary equipment. (Brown et al., (1997) Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis, Lancet, 350: 1531-1537).
  • prostheses containing a rupture indicator include an external envelope of medical grade elastomer containing a fluid material and a biologically compatible chemical indicator for indicating rupture of the prosthesis, and an internal envelope of medical grade elastomer disposed within the external envelope, the internal envelope containing an implant filling material.
  • This publication also describes methods for detecting rupture of a prosthesis, which includes surgically implanting a prosthesis containing a biologically compatible chemical indicator in a location of a patient body in need of the prosthesis; and detecting a change in a bodily secretion, peripheral blood, or locally around the prosthesis for indication of leaking out of the indicator from the prosthesis.
  • the bodily excretion or secretion that can be used, according to WO 2005/039450, for the detection of prosthesis rupture includes materials such as urine, saliva, perspiration and feces.
  • the changes include a presence of the chemical indicator or metabolized product thereof in the bodily excretion, secretion or peripheral blood, an odor from the indicator in the bodily excretion or secretion, a color change of at least one of the body's excretions or secretions, and a change in sensation or taste caused by the presence of the indicator in the bodily secretion.
  • Local skin color change and local x-ray opacity change is also described as indicative of leakage.
  • OFLX started to appear in the hair 1 to 3 days after administration and reached the maximal level approximately 4 to 9 days, remaining at almost the same level thereafter. This finding suggests the slow transfer of OFLX from hair follicle cells to hair matrix may be due to the slow dissociation of OFLX from bound melanin.
  • a filler composition for a prosthesis comprising a tracer that is sequestered in the hair.
  • the tracer is selected from the group consisting of: quinolines, steroids, tricyclic antidepressants, aminoglycosides, beta-2 adrenergic receptor agonists, beta blockers and phthalates.
  • a prosthesis comprising a filler composition, the filler composition comprising a tracer that is sequestered in the hair.
  • the tracer is selected from the group consisting of: quinolines, steroids, tricyclic antidepressants, aminoglycosides, beta-2 adrenergic receptor agonists, beta blockers and phthalates.
  • a prosthesis described herein wherein the tracer is selected from the group consisting of: chloroquine, quinoline, ofloxacin, norfloxacin, temafloxacin, ciprofloxacin, AM 1155, OPC 17116, Q 35, fluorescein, hydrocortisone, dexamethasone, prednisone, imipramine, desipramine, trimipramine, clomipramine, lofepramine, amitriptyline, nortriptyline, protriptyline, dothiepin hydrochloride, doxepin, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin, hygromycin, spectinomycin, clenbuterol, salbutamol, levalbuterol, terbutaline, pirbuterol, procaterol,
  • a prosthesis described herein wherein the tracer is selected from the group consisting of: chloroquine, quinoline, ofloxacin, norfloxacin, temafloxacin, ciprofloxacin, AM 1155, OPC 17116, Q 35, fluorescein, hydrocortisone, dexamethasone, prednisone, imipramine, desipramine, trimipramine, clomipramine, lofepramine, amitriptyline, nortriptyline, protriptyline, dothiepin hydrochloride, doxepin, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin, hygromycin, spectinomycin, clenbuterol, salbutamol, levalbuterol, terbutaline, pirbuterol, procaterol,
  • a prosthesis described herein wherein the prosthesis is selected from the group consisting of breast, buttock, calf, arm, penile, testicular, facial, pectoral, brow, nose, chin, cheek, lip, triceps and biceps.
  • a prosthesis described herein wherein the prosthesis is selected from the group consisting of breast, buttock, chin, cheek, pectoral and testicular.
  • the prosthesis is a breast implant.
  • a method for detecting leakage from a prosthesis comprising a filler comprising a tracer, the method comprising, a) treating a hair sample from a subject having the prosthesis to extract a tracer, thereby obtaining an extract; and b) testing the extract for the tracer, wherein the presence of the tracer or a metabolite thereof in the extract is indicative of a leakage from the prosthesis.
  • a method for detecting leakage from a prosthesis comprising a filler comprising a tracer, the method comprising, a) obtaining a hair sample from a subject having the prosthesis; b) treating the hair sample to extract a tracer thereby obtaining an extract; and c) testing the extract for the tracer, wherein the presence of the tracer or a metabolite thereof in the extract is indicative of leakage from the prosthesis.
  • the tracer is selected from the group consisting of: chloroquine, quinoline, ofloxacin, norfloxacin, temafloxacin, ciprofloxacin, AM 1155, OPC 17116, Q 35, fluorescein, hydrocortisone, dexamethasone, prednisone, imipramine, desipramine, trimipramine, clomipramine, lofepramine, amitriptyline, nortriptyline, protriptyline, dothiepin hydrochloride, doxepin, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin, hygromycin, spectinomycin, clenbuterol, salbutamol, levalbuterol, terbutaline, pirbuterol, procaterol, meta
  • the tracer is selected from the group consisting of: chloroquine, quinoline, ofloxacin, norfloxacin, temafloxacin, ciprofloxacin, AM 1155, OPC 17116, Q 35, fluorescein, hydrocortisone, dexamethasone, prednisone, imipramine, desipramine, trimipramine, clomipramine, lofepramine, amitriptyline, nortriptyline, protriptyline, dothiepin hydrochloride, doxepin, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, paromomycin, hygromycin, spectinomycin, clenbuterol, salbutamol, levalbuterol, terbutaline, pirbuterol, procaterol, meta
  • a method described herein wherein the tracer is ofloxacin.
  • a method described herein wherein the treating comprises base extraction followed by solid phase extraction.
  • the base extraction is sodium hydroxide extraction.
  • the solid phase extraction comprises cation exchange.
  • mass spectrometry Enzyme-linked immunosorbent assay
  • ELISA Enzyme-linked immunosorbent assay
  • UV ultraviolet
  • UV nuclear magnetic resonance
  • GC gas chromatography
  • LC liquid chromatography
  • MPLC medium pressure liquid chromatography
  • HPLC high pressure liquid chromatography
  • TLC thin layer chromatography
  • MS mass spectrometry
  • MS
  • a method described herein wherein the extract is tested using mass spectrometry comprising: a) a container for holding an extracted hair; and b) instructions for hair extraction and delivery of the container.
  • kits described herein further comprising a tool for extracting a hair for providing an extracted hair;
  • a kit described herein further comprising a questionnaire.
  • the questionnaire comprises an envelope for delivery of the container.
  • Figure 1 is a mass spectra of ciprofloxaxin standard using MS.
  • Figure 2 is a mass spectra of ciprofloxaxin standard using MS/MS.
  • Figure 3 is a mass spectra of a NaOH digest of a hair sample, pretreated with ciprofloxacin using MS.
  • Figure 4 is a mass spectra of a NaOH digest of a hair sample, pretreated with ciprofloxacin using MS, zoomed into a region of interest.
  • Figure 5 is a mass spectra of a NaOH digest of a hair sample pretreated with ciprofloxacin using MS.
  • Figure 6 is a mass spectra of a NaOH digest of a hair sample with no ciprofloxaxin using MS.
  • Figure 7 is a mass spectra of a NaOH digest of a hair sample with no ciprofloxaxin using MS, zoomed into a region of interest.
  • Figure 8 is a mass spectra of a NaOH digest of a hair sample with no ciprofloxaxin using MS/MS.
  • Filler compositions for a prosthesis are well known in the art. Typical fillers include silicone, silicone based polymers and saline solutions as well as many others. Fillers of the present invention will comprise any filler composition currently used, known, discovered or invented in the future that also comprise a tracer that is sequestered in the hair.
  • a marker is a compound that can be identified in a tissue or bodily fluid, such as hair, blood, urine, or perspiration if the tissue or bodily fluid has come into contact with the marker.
  • Many marker compounds are known to a person of skill in the art of markers and include members of the quinoline family, steroid family, phtalate family, heavy metals, radio-active compounds, fluorescent compounds and dyes. Other markers include food stuffs such as capsaicin and garlic. Markers for use in the present invention are termed tracers. Some markers are not suitable for use as tracers in the present invention. Tracers, which are markers suitable for use in the present invention, have the following characteristics: sequestered in the hair; a suitable safety profile; suitable stability; suitable affinity for melanin; and suitable solubility.
  • Compounds that are known to be sequestered in the hair and are markers include, without limitation: Ftorafur, codeine, alprazolam, amphetamine, norsteroids, anabolic steroids, endogenous steroids, corticosteroids, anhydroecgonine methyl ester, barbiturate, benzodiazepines, benzoylecgonine, benzphetamines, beta 2 adrenergic agonists, beta blockers, buphrenorphine, caffeine, carbamazepine, chloroquine, ciprofloxacin, clenbuteral, clenbuterol, clonazepam, clozapine, cocaethylene, ***e and metabolites, d-amphetamine, dehydroepiandosterone (DHEA), dextromoramide, dextropropoxyphene, digoxin, dimethylamphetamine, doxepin, N-methyl-D-aspartic acid (MDMA), 2-
  • endogenous steroids including DHEA and testosterone, furancarboxylic acid, thyroxine, ethyl glucuronide and fatty acid ethyl esters because they are normally present in the body; caffeine, cotinine and nicotine because they are common in the environment; Ftorafur because of high toxicity; carbamazepine because it may render oral contraceptives ineffective; phenytoin because it is teratogenic; fluoxetin because it is too commonly used; amphetamine, buphrenorphine cocaethylene (psychoactive) ***e, d-amphetamine, dextromoramide, dimethylamphetamine, MDMA, GHB, heroin, methamphetamine, nor***e (active metabolite), and phencyclidine because they are controlled substances or have psychoactive effects; codeine, norsteroids, anabolic stanozolol, barbiturate, benz
  • tracers for use in the present invention: tetrahydrocannabinol, alprazolam, anhydroecgonine methyl ester, benzphetamines, beta 2 adrenergic agonists, beta blockers, chloroquine, ciprofloxacin, clenbuteral, clenbuterol, cloazepine, clonazepam, clozapine, corticosteroids, dextropropoxyphene, doxepin, EDDP, ephedrine exogenous steroids, fenethylline, terbinafine, meprobamate, methylecgonine, monodesethylchloroquine, norfloxacin, pholcodine, prednisone, ofloxacin, selegiline, temafloxacin, tetrahydrocannabinol, tricyclic antidepressants, and triazolob
  • Compound known to have a suitable safety profile have no acute undesirable effects and are markers include: Vitamin C, dihydrotachysterol, pyridoxine, ergocalciferol, vitamin A, cholecalciferol, niacin, thiamine, riboflavin, ketoconazole, benzophenone, norsteroids, codeine, benzodiazepines, caffeine, carbamazepine, cotinine, DHEA and endogenous steroids, ethyl glucuronide and fatty acid ethyl esters, flunitrazepam, fluoxetin, furancarboxylic acid, nandrolone, nicotine, nordiazepam, oxazepam, stanozolol, testosterone, thyroxine tetrahydrocannabinol, alprazolam, anhydroecgonine methyl ester, benzphetamines, beta 2 adrenergic agonists, beta blockers
  • ketoconazole and benzophenone because they are present in over-the-counter shampoo and sunscreen; nicotine and cotinine because they are common in the environment; vitamin C, dihydrotachysterol, pyridoxine, ergocalciferol, vitamin A, cholecalciferol, niacin, thiamine, riboflavin and caffeine because they are commonly found in food; DHEA, testosterone and endogenous steroids, thyroxine, furancarboxylic acid, ethyl glucuronide and fatty acid ethyl esters because they are naturally found in the body; norsteroids, codeine, benzodiazepines, carbamazepine, flunitrazepam, fluoxetin, nandrolone, nordiazepam, oxazepam, and stanozolol.
  • tracers for use in the present invention: tetrahydrocannabinol, alprazolam, anhydroecgonine methyl ester, benzphetamines, beta 2 adrenergic agonists, beta blockers, chloroquine, ciprofloxacin, clenbuteral, clenbuterol, clonazepam, clozapine, exogenous steroids including corticosteroids and prednisone, dextropropoxyphene, doxepin, EDDP, ephedrine, fenethylline, terbinafine, meprobamate, methylecgonine, monodesethylchloroquine, norfloxacin, pholcodine, ofloxacin, selegiline, temafloxacin, tetrahydrocannabinol, tricyclic antidepressants, and triazolobendiazepine
  • Aminoglycosides fluoroquinolones, chlorpromazine and other phenothiazines, clembuterol, salbutamol, nor-testosterone, trenbolone, diethylsilbestrol, chloroquine, haloperidol, trimipramine, desipramine, sulpiride, benzophenone, ***e, opioides, imipramine, clomipramine, amitryptiline, quinine, iron, nickel, lead, copper.
  • tracers for use in the present invention: lead and ***e for toxic or psychoactive effects; iron, nickel, and quinine because they are common in the environment and tonic water (quinine); nor-testosterone, trenbolone, chlorpromazine and other phenothiazines, sulpiride, haloperidol, and benzophenone.
  • the following are non-limiting examples that may be suitable as tracers for use in the present invention: aminoglycosides, fluoroquinolones, clembuterol, salbutamol chloroquine, trimipramine, desipramine, imipramine, clomipramine, oflaxacin, and amitryptiline,
  • Compounds known to have suitable stability and are markers include: Perhexiline (2-6 days), riluzole (12 hrs), lomustine (metabolites 16-48 hr.) clopidogrel (platelet bound 11 days), progesterone (25-50 hrs), amphotericin B (15 days elimination; 24 hrs from serum), azelastine (22 hrs), cinacalcet (30-40 hrs), benzodiazepines (40-50 hrs.), tiludronate (50 hrs), flurazepam (metabolite 47-100 hrs), donepezil (70 hrs), ciprofloxacin (4 hrs), norfloxacin (3-4 hrs), and cotinine (15-20 hrs).
  • tracers for use in the present invention: Perhexiline and lomustine because they have a small therapeutic window or are toxic, progesterone, cinacalcet, benzodiazepines, flurazepam, and cotinine.
  • the following are non-limiting examples that may be suitable as tracers for use in the present invention: riluzole, clopidogrel, azelastine, donepezil, ciprofloxacin, ofloxacin, and norfloxacin.
  • Compounds known to have suitable solubility and are markers include: Quinine (500 mg/L), ciprofloxacin (1.1 mg/L) THC, hydrocodone, melphalan (0. Ig/ 10OmL), codeine, urea, ethinamate (1500 mg/L), ethotoin (5280 mg/L), fenoldopam (4000 mg/L).
  • Quinine 500 mg/L
  • ciprofloxacin 1.1 mg/L
  • THC hydrocodone
  • melphalan (0. Ig/ 10OmL
  • codeine urea
  • ethinamate 1500 mg/L
  • ethotoin ethotoin (5280 mg/L)
  • fenoldopam 4000 mg/L.
  • fenoldopam because it has a short half life
  • urea because it is naturally present in the body
  • quinine hydrocodone, melphalan
  • codeine The following are non
  • Markers that are unsuitable for use in the present invention are: 1) compounds that cause moderate to severe toxicity, side effects or birth defects; 2) compounds that are common in the environment or are commonly prescribed; 3) compounds that are known to be quickly excreted or degraded in vivo without sequestering in the hair; 4) compounds that would interfere with silicone polymerization or stability of polymerized silicone; and 5) compounds that are not pharmacologically systemic (i.e., serum soluble and tissue permeable).
  • Compounds that may be useful as tracers in the present invention provide compounds that may be detected very soon after a leak occurs and that may be detected long after a leak has occurred.
  • Suitable tracers may be cleared from a biological system via typical metabolic clearance through bodily fluids such as urine, feces, perspiration and blood. Clearance of the tracer via a typical metabolic clearance allows detection of a tracer in a bodily fluid within hours of a prosthesis leak occurring. Suitable tracers may also sequester in the hair. By being able to sequester in the hair, suitable tracers are detectable long after a prosthesis leak occurs. Provided that the appropriate part of the hair is not cut off, the tracer may be detected in the hair many years after the leak has occurred and long after the tracer would have been cleared via a typical metabolic route.
  • bodily fluids such as urine, feces, perspiration and blood. Clearance of the tracer via a typical metabolic clearance allows detection of a tracer in a bodily fluid within hours of a prosthesis leak occurring. Suitable tracers may also sequester in the hair. By being able to sequester in the hair, suitable tracers are detectable long after a
  • Suitable tracers are first able to be detected in the hair from 1 to 3 days after the leakage and are detectable in the hair thereafter.
  • Tracers suitable for use in this invention exhibit properties amenable to a mass-spectrometry-based hair analysis protocol. Such properties include: 1) stability throughout the extraction process; 2) presence of an ionizable group; and 3) mass fingerprint that is distinguishable from all other compounds present in a typical hair sample.
  • tracers for use in the present invention include, without limitation: chloroquine, quinoline, ofloxacin, norfloxacin, temafloxacin, ciprofloxacin, AM-1155, OPC-17116, Q-35, fluorescein, hydrocortisone, dexamethasone, prednisone.
  • the tricyclic antidepressants imipramine, desipramine, trimipramine, clomipramine, lofepramine, amitriptyline, nortriptyline, protriptyline, dothiepin hydrochloride, and doxepin.
  • beta blockers dichloroisoprenaline, practolol, pronethaolol, alprenolol, carteolol, levobunolol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, acebutolol, atenolol, betaxolol, bisoprolol, esmolol, metoprolol, nebivolol, carvedilol, celiprolol, labetalol, butoxamine, Tetrahydrocannabinol, alprazolam, anhydroecgonine methyl ester, benzphetamines, cloazepine, clonazepam, clozapine, dextropropoxyphene,
  • Some of the metabolites of the foregoing list which may also be suitable for use as a tracer or be tested for as indicative of prosthesis leakage may include, without limitation: ofloxacin-N-oxide, desmethyl-ofloxacin, desethylchloroquine, bisdesethylchloroquine, and desmethyl metabolites of tricyclics.
  • Tracers of the present invention may be mixed with typical filler compositions known to a person of skill in the art of prostheses thereby producing fillers comprising tracers. Fillers comprising tracers may then be used to prepare prostheses. Methods of making prostheses are known to a person of skill in the art of prostheses. There are many different sorts of prostheses, including breast, buttock, calf, arm, penile, testicular, facial, pectoral, brow, nose, chin, cheek, lip, triceps and biceps. Prostheses like these and others may be provided with fillers comprising tracers.
  • prostheses are provided with compartments. Each compartment may be provided with tracer or particular compartments may be provided with tracer while some are not provided with a tracer. Furthermore, some compartments may be provided with filler and some compartments may not be provided with filler. The filler in a particular compartment may or may not be mixed with tracer. The tracer in a particular compartment may or may not be mixed with filler. In some illustrative embodiments, prostheses are provided with an exterior membrane and an interior membrane such that the tracer is provided between the two membranes and the filler is provided in inside the interior membrane. The filler provided inside the interior membrane may or may not be mixed with filler. The tracer between the interior and exterior membrane may or may not be mixed with filler.
  • the amount of tracer in a single prosthesis is a therapeutically suitable dose.
  • the amount of tracer to be included in a prosthesis is determined, in part, by the characteristics of the subject receiving the prosthesis and the particular tracer being used.
  • a therapeutically suitable amount of a tracer may vary according to factors such as the age, sex, and weight of the subject, and the ability of the compound to elicit a desired response in the subject.
  • a therapeutically suitable amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects.
  • specific quantities of the tracer may be adjusted according to the individual need and the professional judgement of the person administering or supervising the introduction of the prosthesis.
  • Amount ranges set forth herein are exemplary only and do not limit the quantities that may be selected by medical practitioners.
  • the amount of tracer in the filler may vary according to factors such as the disease state, age, sex, and weight of the subject as well as size and type of the prosthesis.
  • tracers for use in the invention should be used without causing substantial toxicity.
  • Toxicity of tracers for use in the invention can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LDlOO (the dose lethal to 100% of the population).
  • tracers for use in the present invention have been studied in detail with respect to their therapeutically suitable doses.
  • loxacin is tolerated at levels of 200-400 mg every 12 hours for 3-14 days and a single dose up to 2500mg/kg in mice is not lethal.
  • Ciprofloxacin is often prescribed at 500-1000 mg every 24 hours for 3-14 days.
  • Norfloxacin is often prescribed at 400 mg every 12 hours for 3-28 days and also at a single dose of 800mg.
  • Hydrocortisone is known to be lethal in mammals at a dose of 6ml/kg and is often prescribed at a dosage of 20-25 mg/day.
  • Dexamethasone is often prescribed in range of 1-2 mg/kg/day to a maximal level of 4-5 mg/kg in patients with shock.
  • Fluoroscein has a LD50 of 4700 mg/kg (oral dose) in mice and is often injected at about 7mg/kg in patients for retinal imaging.
  • Chloroquine has a LD50 of 500 mg/kg via oral route in mice and is often prescribed at a total dose of 1500 mg given over 48 hours for treatment of malaria.
  • a "subject" may be a human, non-human primate, mammal, domestic pet, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc. It is common for more than one prosthesis to be implanted in a single subject. In such cases, it is possible to select prostheses that contain different tracers. By selecting different tracers for each of the prostheses it is possible to determine which prosthesis is leaking by identifying the tracer that is detected.
  • Methods for detecting leakage from a prosthesis comprise a) obtaining a sample from a subject having the prosthesis; b) treating the sample to extract a tracer thereby obtaining an extract; and c) testing the extract for the tracer or a metabolite thereof.
  • the presence of the tracer or a metabolite thereof in the extract is indicative of a leakage from the prosthesis.
  • Metabolites include, but are not limited to, compounds formed through the endogenous processes of demethylation, oxidation, and/or hydroxylation of parent compounds or their metabolites.
  • a sample may be a bodily fluid obtained from the subject, such as blood, feces, urine, or perspiration or may be a tissue such as hair or a tissue sample from close to the location of the prosthesis in the subject. Methods of obtaining such samples are known to a person of skill in the art. In the particular example when the sample is a hair from the subject, the hair should ideally be removed from the subject by plucking such that the root of the hair is obtained.
  • Hair growth typically occurs at a rate of approximately 1 cm per month for an average person's scalp.
  • the growth rate of a subject's hair can be used to provide information regarding the timing of a leakage. For example, if the sample of hair is cut into measured segments (e.g. lcm, 0.5 cm, 0.25 cm or 0.1cm) and the measuring is achieved by measuring the distance from the root of the hair, then the time that has elapsed since a leakage event may be determined based on which measured segment of hair provides an extract that is positive for the tracer. This may provide information regarding whether or not a particular activity is causing or exacerbates a leak in a prosthesis.
  • measured segments e.g. lcm, 0.5 cm, 0.25 cm or 0.1cm
  • this information may provide information that a medical practitioner may use to prescribe a treatment course based on the timing of the leak.
  • This information also permits a medical practitioner to prescribe the tracer for an alternative treatment (i.e. using the tracer for a therapy unrelated to the prosthesis) and based on the timing of the alternative treatment and the location of the tracer in the hair, a potential false positive may be identified as a false positive.
  • a typical hair sample may be treated by cutting the hair into measured segments, as described above, ordering and recording the order of the hair segments and subjecting each measured segment to a base-digestion (e.g. sodium hydroxide). Following base digestion, solid phase extraction on a cation exchange column or cartridge is performed and the eluate from the column or cartridge is provided as the extract.
  • a base-digestion e.g. sodium hydroxide
  • the extract is then tested for the presence of the tracer or metabolites thereof.
  • Possible testing techniques include, without limitation, Enzyme-linked immunosorbent assay (ELISA), Fluorescence spectroscopy, ultraviolet (UV) spectrometry, nuclear magnetic resonance (NMR), gas chromatography (GC), liquid chromatography (LC, medium pressure liquid chromatography (MPLC), high pressure liquid chromatography (HPLC), thin layer chromatography (TLC), mass spectrometry (MS), tandem MS (MS/MS), LC-MS, GC-MS, HPCL-MS/MS, matrix assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS.
  • ELISA Enzyme-linked immunosorbent assay
  • LC medium pressure liquid chromatography
  • HPLC high pressure liquid chromatography
  • TLC thin layer chromatography
  • MS mass spectrometry
  • MS tandem MS
  • LC-MS LC-MS
  • GC-MS HPCL-MS/MS
  • MALDI-TOF matrix
  • Tracers and their metabolites may be detected in hair at amounts that represent their relative concentration in the sample and because deposition of these compounds in hair is achieved over time in accordance with hair growth, both leakage/rupture severity and duration may be determined depending on the quantity of tracer or metabolite thereof detected.
  • the presence of the tracer ofloxacin or norfloxacin may be detected by respective spectrophotometry excitation and emission at 290nm and 460nm.
  • the presence of the tracer fluoroquinolone may be detected by reverse phase HPLC-MS/MS.
  • HPLC-based approaches may lead to false positive detection if related molecules of similar size and characteristics are present in the sample. This leads to less accurate results if the person has been taking medications or exposed to compounds of similar properties in the environment. False-positive results may complicate identification of the tracer molecule in samples with high confidence, making it difficult to take action when leakage is suspected.
  • Fluorescence-based approaches to determine the presence of the tracer compound may result in false-positive results based on the presence of molecules with similar fluorescent properties. Additionally, fluorescence-based approaches may have a reduced sensitivity due to background fluorescence under baseline conditions. Detection by this technique would require a leakage event releasing levels of tracer high enough to overcome the background fluorescence. This could result in false-negatives for people with small leakage events or event which leak very slowly over a long period of time. Mass spectrometry-based detection allows for highly accurate detection of low levels of molecule in the tested solution (eg. ofloxacin in the range of 1 ng/L of blood; 0.3 ug/L of urine).
  • Mass spectrometry also allows confirmation of the specific molecular size of the target compound, reducing likelihood of false-positive test results, from related molecules. Mass spectrometry can also detect the relative abundance of the specific molecule in the solution at very low levels, without overlap from similar compounds or environmental contaminants. This higher level of specificity increases the confidence in test results, allowing for confirmation of leakage events.
  • a tracer may be used for detecting leakage of a prosthesis. Tracers may be used for detecting the time of leakage of a prosthesis. Alternatively, tracers may be used for detecting the severity of leakage of a prosthesis. The tracer, in addition to being useful as a marker, may also be used for reducing the possibility that infection or serious infection of a subject occurs after leakage of a prosthesis.
  • the tracer is also an antibiotic
  • the antibiotic may act to combat infection, if the leakage is caused, for example, by trauma to the subject in the area of the prosthesis, or a bacterial or fungal contaminant is introduced to the implant during production or implantation.
  • the tracer may have a different alternative therapeutic use and may be suitable for specific application in specific prostheses to be used for specific applications. Many subjects may not have easy accessibility to suitable resources for testing an extract. Alternatively, a subject may not want to take the time to visit a testing facility. In such cases, a kit for submitting a test for prosthesis leakage may be provided to the subject.
  • the kit may include: a) a container for holding a sample; and b) instructions for obtaining a sample and delivery of the container.
  • the container for holding the sample may comprise a variety of known containers, but should be provided so that until the sample is received in the container, the container is kept uncontaminated or sterile.
  • the container should be resealable so that once the sample is received in the container, possible further contamination is reduced or prevented.
  • the container may also be large enough to permit a full sample to be contained within a single container.
  • a plurality of containers may be provided in the kit so that the subject may provide more than one sample, either at the same time or at various intervals throughout time, such as every week, every month, every year, or as often as desired.
  • the instructions for obtaining a sample will provide details of how to obtain a sample so that possible contamination of the sample does not occur or is minimized. Furthermore, the instructions will provide minimum quantities that are required.
  • the container may have markings that provide guidance for the subject when trying to determine is a sample is of a sufficient quantity.
  • the instructions for obtaining a sample will also provide maximum time limits by which a sample must be obtained and then delivered to the testing facility.
  • the delivery location or address of the testing facility to which a sample should be delivered will also be provided in the instructions. The delivery location may be a remote location from which the testing facility picks up samples.
  • kits may be provided with tools for aiding a subject to obtain a sample.
  • tools for aiding a subject to obtain a sample For example, sterile tweezers may be provided for extracting a hair to be provided as a sample. Rubber or latex gloves may be provided also.
  • kits may be provided with a questionnaire.
  • the questionnaire may be generic or specific to a particular tracer or prosthesis.
  • the questionnaire is provided so that a subject may complete the questionnaire in order to provide the testing facility with information, such as medication history of the subject, which may identify a false positive result.
  • the questionnaire may provide information for the testing facility to examine a particular section of the sample or to treat the sample using a particular method or test the extract using a particular method.
  • Tools for aiding the subject to deliver the sample may also be provided, such as envelopes or pre-printed labels.
  • a questionnaire may be provided such that is capable of folding into a holder suitable for holding the container and delivery of the container with the sample.
  • Hair samples received for tracer analysis could be processed as follows:
  • Segmentation Hair strands (single or multiple) are observed under magnification to determine the scalp-proximal or root end. The length of the hair is measured and recorded. The strands are left whole or cut into fragments starting at various points from the scalp-proximal end. Cut fragments may be 5 to 10 mm in length but may be smaller or larger in size as required. The position of fragments relative to the whole hair length is recorded and tracked throughout processing.
  • the hair or fragments are cleaned of external contamination. In some cases washing may not be required. For example, whole hair or hair fragments are washed in 0.1% w/v sodium dodecylsulfate (SDS) in distilled water for 10 minutes with agitation followed by 1 to 3 rinses with distilled water.
  • SDS sodium dodecylsulfate
  • Other reagents that could be used to wash the sample include, but are not limited to: isopropanol; methanol; dichloromethane; acetone; distilled water mixed with acetone; distilled water containing any number from one or more of variety of detergents; and distilled water containing metal chelators (e.g., EDTA).
  • the hair or fragments are digested to release the tracer.
  • whole hair or hair fragments are digested for 30 minutes at 80°C in 1 volume (e.g., 0.5 mL) 1 N sodium hydroxide (NaOH) prepared in distilled water.
  • Other digestion conditions could include, but are not limited to: enzymatic digestion with proteinase K, a glucuronidase/arylsulfatase mixture or other enzymes; methanol extraction for several hours (5- 24 hrs) with or without ultrasonic bath; aqueous extraction in acid (0.01 N - 0.5 N HCl) or phosphate buffer (pH 6 - 8); and extraction with acidic urea and thioglycolate.
  • the digestion reaction are neutralized or otherwise stopped.
  • the digestion reaction is allowed to cool and then neutralized with 1 volume (e.g., 0.5 mL) 1 N hydrochloric acid (HCl) prepared in distilled water.
  • 1 volume e.g., 0.5 mL
  • 1 N hydrochloric acid (HCl) prepared in distilled water.
  • the digested sample is prepared for extraction of the tracer.
  • a preparation step before extraction is not required.
  • 2 volumes e.g., 2 mL
  • 50 mM phosphate buffer pH 8 prepared in distilled water are added to the neutralized digestion reaction.
  • the tracer is extracted using an appropriate solvent, hi some cases solvent extraction is not required.
  • the tracer is extracted using 10 volumes (e.g., 5 mL) of chloroform for 20 minutes with agitation.
  • the organic and aqueous phases may be separated by centrifugation at l,700xg for 5 minutes, hi this example, the organic phase (chloroform) may be recovered for further analysis.
  • Other extraction buffers include, without limitation, organic or aqueous based solvents optimal for the selected tracer including: n-hexane; acetonitrile; acetone; and dichloromethane.
  • the tracer is concentrated or the solvent removed in order to dissolve the tracer in an instrument-compatible solvent.
  • the sample is applied directly without changing the extraction solvent.
  • the organic phase is evaporated under a nitrogen stream at room temperature.
  • the tracer sample is dissolved in a solvent and analyzed by mass spectroscopy.
  • samples of the tracer include an internal marker for quantification and analyzed by mass spectroscopy.
  • the sample is applied directly to a mass spectrometer.
  • the sample is further purified by gas or liquid phase chromatography or other means of purification/sample clean-up before mass spectroscopic analysis.
  • the dried tracer sample is dissolved in 1 volume (e.g., 0.5 mL) 0.1% formic acid prepared in distilled water to which 1 volume (e.g., 0.5 mL) acetonitrile is added.
  • a 'fingerprint' of the tracer is compared to a known spectra of the tracer, a library of hair matrix samples (tracer-negative) prepared from a representative population set and a library of tracer-positive samples within a representative hair matrix sample. Comparison to solutions of known tracer concentration allow accurate quantitation of tracer levels in the tested samples.
  • the representative sets used in the comparison are compiled from hair of a similar pigment and cosmetic treatment (e.g, artificial hair dyes, permanent solution, peroxide or others). For example, a quantity of the prepared sample solution (e.g., 40 microlitres) is injected directly into a Nanospray ionization chamber for MS or tandem MS/MS analysis or other in-line or off-line tandem MS instrumentation methods. 10.
  • a report of the tracer concentration per unit protein mass of hair is then prepared for dissemination to the requester.
  • the mass of the hair is determined by protein analysis methods that may include, but are not limited to: UV spectroscopy, Bradford or similar protein assay, determination of ionized amino acid parent compounds by mass spectroscopy.
  • Either ofloxacin or norfloxacin each prepared in a pharmacologically acceptable carrier including but not limited to 0.9% sodium chloride injection, 5% dextrose injection, 5% dextrose and 0.9% sodium chloride injection, 5% sodium bicarbonate injection, 5% dextrose, 0.45% sodium chloride, and 0.15% potassium chloride injection; 1/6 M sodium lactate injection, is infused within the silicone filler material during breast implant fabrication or filling.
  • the carrier permits ofloxacin/norfloxacin stability, and also permits ofloxacin/norfloxacin diffusion concurrent with silicone diffusion upon induced or spontaneous rupture of the shell of the implant.
  • the implant shell is created or coated so as to limit diffusion of the fluoroquinolone derivative contained within it.
  • the mass of either ofloxacin or norfloxacin within each finished silicone/fluoroquinolone-derivative-filled implant may range between lOmg and 2000mg such that complete release of either ofloxacin or norfloxacin does not result in serum concentrations of either of the two fluoroquinolone derivatives being above clinically acceptable levels.
  • the first implant contains ofloxacin within its filler material
  • the second implant contains norfloxacin within its filler material.
  • any fluoroquinolone derivatives that have leaked from the breast implant, indicating a loss of implant integrity, are detected by their accumulation within patient hair.
  • Patient's hair samples, obtained from the vertex region of the scalp, are cut into 5-10 mm long sections. Order and orientation of the hair samples to the scalp is recorded. Individual hair samples are then subjected to base-digestion followed by solid phase extraction on a strong cation exchange column or cartridge. Eluate from the column is then analyzed for potential fluoroquinolone derivatives by reverse phase high pressure liquid chromatography tandem mass spectrometry (HPLC-MS/MS).
  • presence of ofloxacin and norfloxacin can be detected in the HPLC eluate by respective spectrophotometric excitation and emission at 290nm and 460nm. Because fluoroquinolone derivatives are detected in hair at amounts that represent their relative concentration in serum, and because deposition of these compounds in hair is "recorded" over time in accordance with hair growth, both leakage/rupture severity and duration, respectively, can be determined. Following MS/MS collection, positive detection of ofloxacin or norfloxacin in hair is determined as any detectable level above baseline established on samples lacking ofloxacin or samples from a population of subjects with intact implants containing ofloxacin or norfloxacin.
  • the concentration of ofloxacin or norfloxacin present per mg of hair is calculated based on comparison to spectra collected from solutions of known ofloxacin and norfloxacin concentration.
  • the concentration level of ofloxacin or norfloxacin detected can then be used to estimate levels of leakage from ruptured implants. Any levels of ofloxacin or norfloxacin detected in isolated hair above environmental levels is classified as a positive result for implant leakage requiring intervention by a medical professional.
  • Small-rodent animals such as mice or rats, will be used in the following experiment as model for subglandular breast implants in humans.
  • Animals are surgically implanted with a subcutaneous, fluid- filled silicone implant distal to their thoracic spine. Implants are 2 ml in volume for mice or 5 ml in volume for rats.
  • Ofloxacin is added to the filler of some of the implants, at 2500mg/kg animal weight, during implant filling. A total of 25 animals are used in the experiment, five animals per group, assigned randomly.
  • the groups are treated as follows: 1. intact implants containing ofloxacin, 2. mechanically weakened implants containing ofloxacin, 3. intact implants without ofloxacin, 4. mechanically weakened implants without ofloxacin, 5.
  • Implants are mechanically weakened, introducing a small leak, to simulate leakage events that would occur during the life of a silicone implant in a human subject. Mechanical weakening of the implants is applied following filling, but prior to implantation with a tool that ensures each implant receives consistent mechanical wear.
  • Hair samples are collected every 2 days for the first 8 days, then every month for the first year, and every 4 months for the second year. Samples are kept in a sterile container with the date of preparation noted. Hairs are cut, recording the distance and orientation from the scalp, and digested as outlined above. Following extraction, compounds are assayed by LC/MS/MS as previously described. Isotope-labeled ofloxacin are added to each sample as an internal control to allow quantification of ofloxacin concentration in each hair sample and the location of the tracer along the growing hair (distance from scalp). Laboratory Examples
  • Hair from human volunteers was cut into 5 mm long fragments, discarding the root-end, washed for 10 minutes in 0.1% sodium dodecylsulfate (in distilled water) with agitation, and rinsed a further three times with distilled water. Washed hair fragments were then pre-treated with distilled water with and without ciprofloxacin (10 mg/mL) for 16 hrs at room temperature. The hair fragments were then rinsed three times with distilled water and processed for mass spectroscopy by digestion in 0.5 mL 1 N sodium hydroxide for 30 minutes at 80 0 C. The digestion reaction was neutralized with 0.5 mL 1 N hydrochloric acid and then 1 mL of 50 mM phosphate buffer (pH 8) was added to the mixture.
  • pH 8 50 mM phosphate buffer
  • Chloroform (5 mL) was added to the mixture and the suspension was agitated at room temperature for 20 minutes followed by centrifugation at 1,700 g for five minutes to separate the organic and aqueous phases. The organic phase was then recovered and dried under a nitrogen stream at room temperature or evaporated at low pressure. The residue was dissolved in 0.5 mL 0.5% formic acid prepared in distilled water to which 0.5 mL acetonitrile was added. This solution was then applied to a mass spectrometer instrument for MS or MS/MS analysis. In parallel, a small quantity of pure ciprofloxacin was diluted in 0.5 mL NaOH and processed as described above as a standard.
  • the parent compound peak 332.3 is not visible until the region of interest is expanded (Spectra4 in Figure 4). MS/MS filtering of the 332.3 region reveals peaks corresponding to the expected analytes and parent compound (245.0, 288.0, 314.0, and 332.0) (Spectra 5; Figure 5). As can be seen in the control hair sample not pretreated with ciprofloxacin, a similar peak to the parent compound (332.2) is visible, but the expected analytes (245.0, 288.0, and 314.0) are not visible (Spectra 6, 7 and 8 in Figures 6, 7 and 8 resepctively).

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'un marqueur destiné à être enfermé dans un poil pour détecter la fuite d'une prothèse. L'invention concerne aussi l'utilisation d'un marqueur à enfermer dans un poil afin de détecter le moment de la fuite d'une prothèse. L'invention concerne encore l'utilisation d'un marqueur à enfermer dans un poil afin de détecter la gravité de la fuite d'une prothèse. L'invention propose une composition de remplissage pour une prothèse comprenant un marqueur qui est enfermé dans le poil. En outre, l'invention concerne une prothèse comprenant une composition de remplissage, la composition de remplissage comprenant un marqueur qui est enfermé dans le poil. Des procédés pour détecter une fuite d'une prothèse sont aussi proposés. Les procédés comprennent souvent : a) de traiter un échantillon de poil d'un sujet ayant une prothèse pour extraire le marqueur, afin d'obtenir de cette manière un extrait ; et b) de tester l'extrait à la recherche du marqueur, dans lequel la présence du marqueur ou d'un métabolite de celui-ci dans l'extrait indique une fuite de la prothèse. Des kits pour réaliser un test de la fuite de la prothèse sont aussi proposés.
PCT/CA2007/000818 2006-05-09 2007-05-09 marqueur enferme dans un poil destine a detecter la fuite d'une prothese WO2007128133A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79873406P 2006-05-09 2006-05-09
US60/798,734 2006-05-09

Publications (1)

Publication Number Publication Date
WO2007128133A1 true WO2007128133A1 (fr) 2007-11-15

Family

ID=38667387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2007/000818 WO2007128133A1 (fr) 2006-05-09 2007-05-09 marqueur enferme dans un poil destine a detecter la fuite d'une prothese

Country Status (1)

Country Link
WO (1) WO2007128133A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771964B2 (en) 2012-02-02 2014-07-08 Siemens Healthcare Diagnostics Inc. Compositions and methods for detection of methadone metabolite

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582298A (en) * 1995-05-16 1996-12-10 Uarco Incorporated Business form including a sampling kit
US6478750B1 (en) * 2000-11-17 2002-11-12 Janet F. Morrison Hair collection device and methods of use thereof
US6607699B1 (en) * 2000-08-03 2003-08-19 Her Majesty The Queen In Right Of Canada, As Represented By The Solicitor General Acting Through The Commissioner Of The Royal Canadian Mounted Police Hair root collection kit
WO2005039450A1 (fr) * 2003-10-17 2005-05-06 Tonaba Healthscience, Llc. Prothese reconstructive et cosmetique contenant un indicateur de rupture biologiquement compatible
US20060111632A1 (en) * 2004-11-19 2006-05-25 Fulfillium, Inc. Wireless breach detection
WO2006119243A2 (fr) * 2005-04-29 2006-11-09 William Marsh Rice University Outil diagnostique non invasif diagnostic detectant l'integrite structurelle d'un implant rempli de fluide
WO2006135857A2 (fr) * 2005-06-10 2006-12-21 Novalert, Inc. Procede et dispositif pour surveiller des implants

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582298A (en) * 1995-05-16 1996-12-10 Uarco Incorporated Business form including a sampling kit
US6607699B1 (en) * 2000-08-03 2003-08-19 Her Majesty The Queen In Right Of Canada, As Represented By The Solicitor General Acting Through The Commissioner Of The Royal Canadian Mounted Police Hair root collection kit
US6478750B1 (en) * 2000-11-17 2002-11-12 Janet F. Morrison Hair collection device and methods of use thereof
WO2005039450A1 (fr) * 2003-10-17 2005-05-06 Tonaba Healthscience, Llc. Prothese reconstructive et cosmetique contenant un indicateur de rupture biologiquement compatible
US20060111632A1 (en) * 2004-11-19 2006-05-25 Fulfillium, Inc. Wireless breach detection
WO2006119243A2 (fr) * 2005-04-29 2006-11-09 William Marsh Rice University Outil diagnostique non invasif diagnostic detectant l'integrite structurelle d'un implant rempli de fluide
WO2006135857A2 (fr) * 2005-06-10 2006-12-21 Novalert, Inc. Procede et dispositif pour surveiller des implants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MIZUNO A. ET AL.: "Simultaneous determination of ofloxacin, norfloxacin and ciprofloxacin in human hair by high-performance liquid chromatography and fluorescence detection", J. CHROMATOGR. B. BIOMED. APPL., vol. 653, no. 2, March 1994 (1994-03-01), pages 187 - 193 *
MRYAZAWA N. ET AL.: "Ofloxacin in human hair determined by high performance liquid chromatography", FORENSIC SCI. INT., vol. 51, no. 1, October 1991 (1991-10-01), pages 65 - 77 *
UEMATSU T. ET AL.: "The measurement of ofloxacin in hair as an index of exposure", EUR. J. CLIN. PHARMACOL., vol. 40, no. 6, 1991, pages 581 - 584 *
UEMATSU T. ET AL.: "Time course of appearance of ofloxacin in human scalp hair after oral administration", THER. DRUG MONIT., vol. 17, no. 1, February 1995 (1995-02-01), pages 101 - 103 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8771964B2 (en) 2012-02-02 2014-07-08 Siemens Healthcare Diagnostics Inc. Compositions and methods for detection of methadone metabolite
US9777069B2 (en) 2012-02-02 2017-10-03 Siemens Healthcare Diagnostics Inc. Compositions and methods for detection of methadone metabolite

Similar Documents

Publication Publication Date Title
Cone et al. The potential for bias in hair testing for drugs of abuse
Barroso et al. Hair: a complementary source of bioanalytical information in forensic toxicology
Madej Analysis of meconium, nails and tears for determination of medicines and drugs of abuse
Kennedy et al. Treatment of chronic rhinosinusitis with high‐dose oral terbinafine: a double blind, placebo‐controlled study
Boumba et al. Hair as a biological indicator of drug use, drug abuse or chronic exposure to environmental toxicants
Gallardo et al. The role of alternative specimens in toxicological analysis
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
Cho et al. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs
Daglish et al. Brain imaging studies in human addicts
Mochizuki et al. Guidelines for the management of dermatomycosis (2019)
CN103108633A (zh) TrkB激动剂及其用途
Desrosiers et al. Oral fluid and plasma 3, 4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration
Favretto et al. Occupational exposure to ketamine detected by hair analysis: a retrospective and prospective toxicological study
WO2007041452A2 (fr) Procedes de preparation de tissus organiques vivants destines a etre examines
CN107949379A (zh) L‑4‑氯代犬尿氨酸的治疗用途
Chan et al. Urinary excretion of free toluenediamines in a patient with polyurethane-covered breast implants
WO2013083040A1 (fr) Application de la fluoxétine au traitement de maladies de dépigmentation
JP4228048B2 (ja) 神経変性障害の検出方法
EP4232047A1 (fr) Utilisation de benzodiazépines pour augmenter la sensibilité à la psilocybine suite à un régime de ssri chronique
WO2007128133A1 (fr) marqueur enferme dans un poil destine a detecter la fuite d'une prothese
KR102216923B1 (ko) 마이크로니들 패치를 포함하는 최소 침습적 피부 색소침착 정도 평가 키트 및 피부 색소침착 정도 평가를 위한 바이오마커
KR102216945B1 (ko) 마이크로니들 패치를 포함하는 최소 침습적 주관적 자극성 민감피부 정도 평가 키트 및 주관적 자극성 민감피부 정도 평가를 위한 바이오마커
US9176146B2 (en) Methods of treating autism spectrum disorders and compositions for same
KR102216910B1 (ko) 마이크로니들 패치를 포함하는 최소 침습적 피부주름 또는 피부탄력 진단 키트
Piekoszewski et al. Determination of opiates in serum, saliva and hair addicted persons

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07719742

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07719742

Country of ref document: EP

Kind code of ref document: A1